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A subset of melanoma patients has evidence for sponta-
neous anti-tumor immune responses and T cell infiltration
into tumor sites, which has important prognostic value
and is associated with clinical responses to immunothera-
pies. However, the molecular mechanisms explaining
absence of a T cell response in the majority of patients are
not defined. Analyses of human melanoma metastases by
exome sequencing, gene expression profiling, and IHC
have revealed that many tumors that lack a T cell signa-
ture show alterations in the Wnt/b-catenin signaling path-
way. To investigate if constituently active b-catenin
signaling within the tumor cells might inhibit immune
responses, we utilized an inducible autochthonous mouse
melanoma model driven by inducible BrafV600E and
PTEN-deletion, with or without inducible expression of
active b-catenin. While Braf/PTEN melanomas showed
presence of a modest T cell infiltrate, T cells were nearly
completely eliminated in tumors expressing active
b-catenin. The T cells that were present in the Braf/PTEN
tumors showed an exhausted phenotype as what has been
seen in transplanted tumor models, and therapeutic
efficacy of combination therapy using aCTLA4 with
aPD-L1 mAbs was limited to Braf/PTEN tumors. To test
whether the lack of T cell infiltration was due to a defect
in early T cell priming, these mice were additionally bred
to inducibly express the SIY model antigen within the
developing tumors. Adoptive transfer of 2C TCR Tg
SIY-specific T cells revealed defective spontaneous T cell
priming when tumors expressed active b-catenin. Analysis
of the antigen-presenting cell compartment revealed a
selective decrease in the CD103+ DC subset within the
tumor microenvironment, and T cell infiltration could be
restored by intra-tumoral injection of FLT3-ligand-derived
dendritic cells. The lack of CD103+ dermal dendritic cells
was associated with reduced expression of the chemokines
CCL4 and CXCL1. Surprisingly we identified that tumor
cells themselves as the major chemokine source in Braf/
PTEN tumors, while tumors with active b-catenin signal-
ing lacked expression of those chemokines. Therefore, our
data have identified the first defined molecular pathway in
tumor cells that results in defective spontaneous anti-
tumor T cell responses, an observation with important
implications for cancer immunotherapy.
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